鼻咽癌诊治

教育和培训经历：
　　中山大学　 博士　 2008-09至2011-07 
　　中山大学　 硕士　 2006-09至2008-07　 
　　新乡医学院　学士　2001-09至2006-07 
 
专业工作经历：
    主治医生　 中山大学肿瘤防治中心　 2013-08至今 
    住院医生　 中山大学肿瘤防治中心　 2011-08至2013-08

发表论文：

    1) Lu X, Qian CN, Mu YG, et al. Serum CCL2 and serum TNF-α — two new biomarkers predict bone invasion, posttreatment distant metastases and poor overall survival in nasopharyngeal carcinoma. European J Cancer, 2011;47(3):339-46. ( IF：4.944 )

　　2) Lu X, Xiang YQ, Cao SM, et al. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in the patients with nasopharyngeal carcinoma: more distant metastases and shorter overall survival after treatment. Head and Neck Journal, 2011;33(6):780-5 (IF：2.283 )

　　3) Lu X, Guo X, Hong MH, et al. Comparison of the short-term efficacy of two inductive chemotherapy regimens for locally advanced nasopharyngeal caricinoma: docetaxal plus carboplatin versus 5-fluorouracil plus carboplatin. Chin J Cancer. 2010; 29(2): 140-4.

　　4) Lu X, Wang FL, Guo X, et al. Favorable survival of female patients with nasopharyngeal carcinoma.　Chin J Cancer. 2012 Sep 17. [Epub ahead of print]

　　5) Li SW, Wang H, Xiang YQ, Zhang HB, Lu X, Xia WX, Zeng MS, Mai HQ, Hong MH, Guo X. Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epstein-Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma. Head Neck. 2012 May 18. [Epub ahead of print]

　　6) Zhang H, Xia W, Lu X, Sun R, Wang L, Zheng L, Ye Y, Bao Y, Xiang Y, Guo X. A novel statistical prognostic score model that includes serum CXCL5 levels and clinical classification predictsrisk of disease progression and survival of nasopharyngeal carcinoma patients. PLoS One. 2013;8(2):e57830. doi: 10.1371/journal.pone.0057830. Epub 2013 Feb 28.

　　7) Xia WX, Zhang HB, Shi JL, Lu X, Wang L, Ye YF, Cao KJ, Qian CN, Guo X, Xiang YQ.A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment serum C-reactive protein and N-classification. Eur J Cancer. 2013 Apr 6. pii: S0959-8049(13)00188-3. doi: 10.1016/j.ejca.2013.03.003. [Epub ahead of print]